The CL3 containment suite will be used for CCL’s own diagnostic testing, as well as for client projects.
The Select MDx test that we run at Cambridge Clinical Laboratories is now available through BMI Healthcare. The test is a non-invasive urine test to improve patient selection for prostate cancer diagnostic biopsy and therefore will alleviate many from going through the invasive biopsy.
Read MoreFollowing its recent acquisition from Novacyt Group, the Milton based pathology services company formerly known as Lab 21, has relaunched as Cambridge Clinical Laboratories (CCL). The new owner, Cambridge Pathology BV, has already invested thousands into the company in new equipment and staff.
Read More
